Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 4692 · Homeopathic Drug Product Safety, Quality, and Transparency Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 321 Definitions; generally

+17 −01 of 3 shown
More for 21 U.S.C. § 321
Read § 321Only this section
3 changes the bill asks for here, 1 carried out
  1. Not carried out:

    in paragraph (p), by striking except a new animal drug or an animal feed bearing or containing a new animal drug each place it appears and inserting except a new animal drug, an animal feed bearing or containing a new animal drug, or a homeopathic drug product;

    The bill points to paragraph (p) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (p) in /us/usc/t21/s321
  2. Not carried out:

    in paragraph (v), by adding at the end the following: A homeopathic drug product is not a new animal drug.; and

    The bill points to paragraph (v) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (v) in /us/usc/t21/s321
  3. Carried out:

    by adding at the end the following:(tt) (1) The term “homeopathic drug product” means a drug that— (A) contains 1 or more homeopathic ingredients; and (B) contains no other active ingredient. (2) The term “homeopathic ingredient” means an ingredient— (A) listed in the Homeopathic Pharmacopoeia of the United …

§ 321(ss)–(tt)

Start of § 321 to (ss) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(ss)(1)(1) (1)
an infant formula; oran infant formula; or
(ss)(2)(2) (2)
a medical food, as defined in section 360ee(b)(3) of this title.a medical food, as defined in section 360ee(b)(3) of this title.
(tt)(tt) [inserted: ]
(tt)(1)(1) [inserted: ]
[inserted: The term “homeopathic drug product” means a drug that—]
(tt)(1)(A)(A) [inserted: ]
[inserted: contains 1 or more homeopathic ingredients; and]
(tt)(1)(B)(B) [inserted: ]
[inserted: contains no other active ingredient.]
(tt)(2)(2) [inserted: ]
[inserted: The term “homeopathic ingredient” means an ingredient—]
(tt)(2)(A)(A) [inserted: ]
[inserted: listed in the Homeopathic Pharmacopoeia of the United States or a State homeopathic formulary; or]
(tt)(2)(B)(B) [inserted: ]
[inserted: prepared pursuant to—]
(tt)(2)(B)(i)(i) [inserted: ]
[inserted: homeopathic manufacturing methods and safety and quality standards described in the Homeopathic Pharmacopoeia of the United States or any other officially recognized homeopathic pharmacopoeia; and]
(tt)(2)(B)(ii)(ii) [inserted: ]
[inserted: other standards recognized by the Secretary.]

21 U.S.C. § 343 Misbranded food

+2 −0Shown
More for 21 U.S.C. § 343
Read § 343Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 403 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343) is amended by adding at the end the following:(z) If it is a dietary supplement and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary..

§ 343(x)–(z)

Start of § 343 to (w)(7)(C) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(x)(x) Nonmajor food allergen labeling requirements(x) Nonmajor food allergen labeling requirements
Notwithstanding subsection (g), (i), or (k), or any other law, a spice, flavoring, coloring, or incidental additive that is, or that bears or contains, a food allergen (other than a major food allergen), as determined by the Secretary by regulation, shall be disclosed in a manner specified by the Secretary by regulation.Notwithstanding subsection (g), (i), or (k), or any other law, a spice, flavoring, coloring, or incidental additive that is, or that bears or contains, a food allergen (other than a major food allergen), as determined by the Secretary by regulation, shall be disclosed in a manner specified by the Secretary by regulation.
(y)(y) Dietary supplements(y) Dietary supplements
If it is a dietary supplement that is marketed in the United States, unless the label of such dietary supplement includes a domestic address or domestic phone number through which the responsible person (as described in section 379aa–1 of this title) may receive a report of a serious adverse event with such dietary supplement.If it is a dietary supplement that is marketed in the United States, unless the label of such dietary supplement includes a domestic address or domestic phone number through which the responsible person (as described in section 379aa–1 of this title) may receive a report of a serious adverse event with such dietary supplement.
(z)(z) [inserted: ]
[inserted: If it is a dietary supplement and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary.]

21 U.S.C. § 352 Misbranded drugs and devices

+2 −0Shown
More for 21 U.S.C. § 352
Read § 352Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:(hh) If it is a drug that is not a homeopathic drug product, and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary..

§ 352(gg)–(hh)

Start of § 352 to (gg)(2)(E) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(gg)(2)(F)(F) (F)
product-related programs or services; andproduct-related programs or services; and
(gg)(2)(G)(G) (G)
factual presentations of results from studies that do not characterize or make conclusions regarding safety or efficacy.factual presentations of results from studies that do not characterize or make conclusions regarding safety or efficacy.
(hh)(hh) [inserted: ]
[inserted: If it is a drug that is not a homeopathic drug product, and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary.]

21 U.S.C. § 360eee Definitions

+1 −1Shown
More for 21 U.S.C. § 360eee
Read § 360eeeOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 581(13) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360eee(13)) is amended by striking homeopathic drugs marketed in accordance with applicable guidance under this Act and inserting homeopathic drug products marketed in accordance with this Act.

§ 360eee(12)–(15)

Start of § 360eee to (11)(B) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(12)(12) Prescription drug(12) Prescription drug
The term “prescription drug” means a drug for human use subject to section 353(b)(1) of this title.The term “prescription drug” means a drug for human use subject to section 353(b)(1) of this title.
(13)(13) Product(13) Product
The term “product” means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized products before reconstitution), but for purposes of section 360eee–1 of this title, does not include blood or blood components intended for transfusion, radioactive drugs or radioactive biological products (as defined in section 600.3(ee) of title 21, Code of Federal Regulations) that are regulated by the Nuclear Regulatory Commission or by a State pursuant to an agreement with such Commission under section 2021 of title 42, imaging drugs, an intravenous product described in clause (xiv), (xv), or (xvi) of paragraph (24)(B), any medical gas (as defined in section 360ddd of this title), homeopathic [struck: drugs] marketed in accordance with [struck: applicable guidance under ]this [struck: chapter], or a drug compounded in compliance with section 353a or 353b of this title.The term “product” means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized products before reconstitution), but for purposes of section 360eee–1 of this title, does not include blood or blood components intended for transfusion, radioactive drugs or radioactive biological products (as defined in section 600.3(ee) of title 21, Code of Federal Regulations) that are regulated by the Nuclear Regulatory Commission or by a State pursuant to an agreement with such Commission under section 2021 of title 42, imaging drugs, an intravenous product described in clause (xiv), (xv), or (xvi) of paragraph (24)(B), any medical gas (as defined in section 360ddd of this title), homeopathic [inserted: drug] [inserted: products ]marketed in accordance with this [inserted: Act], or a drug compounded in compliance with section 353a or 353b of this title.
(14)(14) Product identifier(14) Product identifier
The term “product identifier” means a standardized graphic that includes, in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization, the standardized numerical identifier, lot number, and expiration date of the product.The term “product identifier” means a standardized graphic that includes, in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization, the standardized numerical identifier, lot number, and expiration date of the product.
(15)(15) Quarantine(15) Quarantine
The term “quarantine” means the storage or identification of a product, to prevent distribution or transfer of the product, in a physically separate area clearly identified for such use or through other procedures.The term “quarantine” means the storage or identification of a product, to prevent distribution or transfer of the product, in a physically separate area clearly identified for such use or through other procedures.

Rest of § 360eee unchanged

21 U.S.C. § 362 Misbranded cosmetics

+2 −0Shown
More for 21 U.S.C. § 362
Read § 362Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 602 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 362) is amended by adding at the end the following:(g) If it is a cosmetic and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary..

§ 362(e)–(g)

Start of § 362 to (d) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(e)(e) (e)
If it is a color additive, unless its packaging and labeling are in conformity with such packaging and labeling requirements, applicable to such color additive, as may be contained in regulations issued under section 379e of this title. This paragraph shall not apply to packages of color additives which, with respect to their use for cosmetics, are marketed and intended for use only in or on hair dyes (as defined in the last sentence of section 361(a) of this title).If it is a color additive, unless its packaging and labeling are in conformity with such packaging and labeling requirements, applicable to such color additive, as may be contained in regulations issued under section 379e of this title. This paragraph shall not apply to packages of color additives which, with respect to their use for cosmetics, are marketed and intended for use only in or on hair dyes (as defined in the last sentence of section 361(a) of this title).
(f)(f) (f)
If its packaging or labeling is in violation of an applicable regulation issued pursuant to section 1472 or 1473 of title 15.If its packaging or labeling is in violation of an applicable regulation issued pursuant to section 1472 or 1473 of title 15.
(g)(g) [inserted: ]
[inserted: If it is a cosmetic and its labeling bears the term “homeopathic”, “homeopathy”, “homeopath”, or such similar term as is determined by the Secretary.]

21 U.S.C. § 379aa Serious adverse event reporting for nonprescription drugs

+3 −32 of 3 shown
More for 21 U.S.C. § 379aa
Read § 379aaOnly this section
3 changes the bill asks for here, 2 carried out
  1. Carried out:

    in the section heading, by inserting and homeopathic drug products after nonprescription drugs;

  2. Not carried out:

    by inserting or homeopathic drug product after nonprescription drug each place it appears (other than in subsection (a)(2)); and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: inserting QTEXT after QTEXT each place it appears (other than in subsection (X) (X)); and
  3. Carried out:

    by inserting or homeopathic drug products after nonprescription drugs each place it appears.

§ 379aa(a)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 379aa. Serious adverse event reporting for nonprescription drugs§ 379aa. Serious adverse event reporting for nonprescription drugs[inserted: and homeopathic drug products]
(a)(a) Definitions(a) Definitions
In this section:In this section:
(a)(1)(1) Adverse event(1) Adverse event
The term “adverse event” means any health-related event associated with the use of a nonprescription drug that is adverse, including—The term “adverse event” means any health-related event associated with the use of a nonprescription drug that is adverse, including—

§ 379aa(c)–(e)

(a)(1)(A)–(c)(3) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(4)(4) Exemption(4) Exemption
The Secretary, after providing notice and an opportunity for comment from interested parties, may establish an exemption to the requirements under paragraphs (1) and (2) if the Secretary determines that such exemption would have no adverse effect on public health.The Secretary, after providing notice and an opportunity for comment from interested parties, may establish an exemption to the requirements under paragraphs (1) and (2) if the Secretary determines that such exemption would have no adverse effect on public health.
(d)(d) Contents of reports(d) Contents of reports
Each serious adverse event report under this section shall be submitted to the Secretary using the MedWatch form, which may be modified by the Secretary for nonprescription drugs, and may be accompanied by additional information.Each serious adverse event report under this section shall be submitted to the Secretary using the MedWatch form, which may be modified by the Secretary for nonprescription drugs[inserted: or homeopathic drug products], and may be accompanied by additional information.
(e)(e) Maintenance and inspection of records(e) Maintenance and inspection of records
(e)(1)(1) Maintenance(1) Maintenance
The responsible person shall maintain records related to each report of an adverse event received by the responsible person for a period of 6 years.The responsible person shall maintain records related to each report of an adverse event received by the responsible person for a period of 6 years.

§ 379aa(g)–(h)

(e)(2)–(f)(2) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(g)(g) Rule of construction(g) Rule of construction
The submission of any adverse event report in compliance with this section shall not be construed as an admission that the nonprescription drug involved caused or contributed to the adverse event.The submission of any adverse event report in compliance with this section shall not be construed as an admission that the nonprescription drug involved caused or contributed to the adverse event.
(h)(h) Preemption(h) Preemption
(h)(1)(1) In general(1) In general
No State or local government shall establish or continue in effect any law, regulation, order, or other requirement, related to a mandatory system for adverse event reports for nonprescription drugs, that is different from, in addition to, or otherwise not identical to, this section.No State or local government shall establish or continue in effect any law, regulation, order, or other requirement, related to a mandatory system for adverse event reports for nonprescription drugs[inserted: or homeopathic drug products], that is different from, in addition to, or otherwise not identical to, this section.
(h)(2)(2) Effect of section(2) Effect of section
(h)(2)(A)(A) In general(A) In general
Nothing in this section shall affect the authority of the Secretary to provide adverse event reports and information to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, under a memorandum of understanding between the Secretary and such State, territory, or political subdivision.Nothing in this section shall affect the authority of the Secretary to provide adverse event reports and information to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, under a memorandum of understanding between the Secretary and such State, territory, or political subdivision.

Rest of § 379aa unchanged

42 U.S.C. § 262 Regulation of biological products

+1 −1Shown
More for 42 U.S.C. § 262
Read § 262Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended by adding at the end the following: Such term does not include a homeopathic drug product (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act)..

§ 262(i)“Biological product” defined(1)–(2)

Start of § 262 to (h) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(i)(i) “Biological product” defined(i) “Biological product” defined
In this section:In this section:
(1)(1) (1)
The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.[inserted: Such term does not include a homeopathic drug product (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act).]
(2)(2) (2)
The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means—The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means—
(2)(A)(A) (A)
that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; andthat the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and

Rest of § 262 unchanged

Step through the changes